TY - JOUR

T1 - Blood-Based miRNA Panels for Timely Detection of Non-Small-Cell Lung Cancer: From Biomarker Discovery to Clinical Translation

AU - Zedan, Yazan

AU - Konoshenko, Maria Yurievna

AU - Bryzgunova, Olga Evgenievna

AU - Ilyushchenko, Antonina Aleksandrovna

AU - Danilova, Yaroslava Mikhailovna

AU - Gorbunkov, Stanislav Dmitrievich

AU - Zykov, Kirill Alekseevich

AU - Laktionov, Pavel Petrovich

N1 - This work was funded by the Russian State-funded project for the FBSI “Research Institute of Pulmonology” of the FMBA of Russia (grant number 388-03-2024-136) and supported by the Russian State-funded project for ICBFM SB RAS (grant number 125012900932-4).

PY - 2025/12/14

Y1 - 2025/12/14

N2 - Lung cancer (LC) remains a leading cause of global cancer mortality, driving the need for novel timely detection strategies, i.e., stages I-II detection when tumor curation is efficient. Circulating microRNA (miRNAs), with their unique stability in biofluids, offer a powerful approach for non-invasive detection. This review compiles validated miRNAs implicated in the early stages of non-small-cell lung cancer (NSCLC), elucidating their roles in key oncogenic pathways such as epithelial-mesenchymal transition (EMT), PI3K/AKT/mTOR, and JAK-STAT, which regulate proliferation, apoptosis, and metastasis. Furthermore, we critically evaluate developed miRNA panels with a specific focus on advanced quantification and normalization strategies, including exogenous spike-in controls and data-driven methods like pairwise normalization, to enhance diagnostic accuracy. Consequently, we identify and rank the most viable miRNA candidates according to key analytical and clinical metrics, providing a clear roadmap for translating these biomarkers into effective panels for the timely detection of NSCLC.

AB - Lung cancer (LC) remains a leading cause of global cancer mortality, driving the need for novel timely detection strategies, i.e., stages I-II detection when tumor curation is efficient. Circulating microRNA (miRNAs), with their unique stability in biofluids, offer a powerful approach for non-invasive detection. This review compiles validated miRNAs implicated in the early stages of non-small-cell lung cancer (NSCLC), elucidating their roles in key oncogenic pathways such as epithelial-mesenchymal transition (EMT), PI3K/AKT/mTOR, and JAK-STAT, which regulate proliferation, apoptosis, and metastasis. Furthermore, we critically evaluate developed miRNA panels with a specific focus on advanced quantification and normalization strategies, including exogenous spike-in controls and data-driven methods like pairwise normalization, to enhance diagnostic accuracy. Consequently, we identify and rank the most viable miRNA candidates according to key analytical and clinical metrics, providing a clear roadmap for translating these biomarkers into effective panels for the timely detection of NSCLC.

KW - Humans

KW - Carcinoma, Non-Small-Cell Lung/genetics

KW - Lung Neoplasms/genetics

KW - Biomarkers, Tumor/blood

KW - MicroRNAs/blood

KW - Epithelial-Mesenchymal Transition/genetics

KW - Circulating MicroRNA/blood

KW - Gene Expression Regulation, Neoplastic

KW - Early Detection of Cancer

UR - https://www.scopus.com/pages/publications/105025756061

U2 - 10.3390/ijms262412035

DO - 10.3390/ijms262412035

M3 - Review article

C2 - 41465462

VL - 26

JO - International Journal of Molecular Sciences

JF - International Journal of Molecular Sciences

SN - 1661-6596

IS - 24

M1 - 12035

ER -